Skip to nav Skip to content

A doctor showing a woman her brain MRI

It’s understandable for meningioma survivors to worry about a recurrence, meaning their cancer coming back after it goes into remission. Around 20 percent of survivors are diagnosed with recurrent meningioma, but these tumors are often just as treatable as primary meningiomas. However, because it’s always important to watch for potential signs of a recurrence, oncologists typically schedule patients for routine, follow-up imaging scans after treatment is complete to help detect any unusual changes as soon as they occur.

Although it’s not possible to predict with any level of certainty whether a patient will experience a meningioma recurrence, certain studies have found recurrence rates to be slightly higher among the patients who

  • Were initially diagnosed with atypical (grade 2) or malignant (grade 3) meningiomas
  • Were initially diagnosed with parasagittal, convexity or sphenoid wing meningiomas
  • Underwent a partial resection (surgery to remove part of a tumor) rather than a complete resection (surgery to remove an entire tumor)
  • Did not receive radiation therapy after surgery

A growing number of molecular genetic alterations have been identified that are associated with more aggressive tumor behavior. In the future, the use of molecular markers in meningioma classification may improve the prediction of the tumor biologic behavior and prognosis.

At Moffitt Cancer Center, our oncologists consider these factors, along with others, when planning a patient’s treatment and follow-up schedule. Plus, we take every step possible to help our patients take a proactive role in monitoring their own health. Education is key, and we give our patients the tools they need to recognize the warning signs of a potential meningioma recurrence. Our oncologists also use the most advanced imaging technologies available to help detect cellular changes as soon as they occur, providing even more peace of mind for our patients.

check mark symbol Medically reviewed by Andre Beer Furlan, MD, PhD, skull base and endovascular neurosurgeon, Neuro-Oncology Program.

Referrals are not required to come to Moffitt, whether for initial treatment or follow-up monitoring. To consult with one of our oncologists specializing in brain cancer regarding a potential meningioma recurrence, call 1-888-663-3488 or submit a new patient registration form online.